Cyberonics Resumes Bid For Depression Indication, Submits Two-Year Data
This article was originally published in The Gray Sheet
Executive Summary
Cyberonics is betting that two-year follow-up data from 240 depression patients treated with VNS Therapy will allay FDA's concerns about inherent trial bias in its non-randomized pivotal study
You may also be interested in...
Cyberonics Depression Approval Contingent On Dosing Trial, Registry
Cyberonics will start a 450-patient, three-year dosing trial in order to gain PMA approval for its VNS Therapy neuromodulation device for use in treatment-resistant depression patients
Cyberonics Depression Approval Contingent On Dosing Trial, Registry
Cyberonics will start a 450-patient, three-year dosing trial in order to gain PMA approval for its VNS Therapy neuromodulation device for use in treatment-resistant depression patients
Cyberonics Hits A Nerve: FDA Issues Firm Warning Letter For QSR Deficiencies
FDA's warning letter citing Cyberonics for quality system regulation lapses presents a further challenge for the device company as it seeks approval for a depression indication